tirzepatide surpass cvot SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized SURPASS-CVOT trial: Tirzepatide was non-inferior

But the next generationled by retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptorsis showing even more profound benefits

This aligns with recommendations that 20%35% of your daily calories should come from fat

Women with larger waistlines face more than double the risk of developing heart disease

Postmenopausal osteoporosis

Click for more information Vitamin C Good for your immune defence system, protection from viruses and bacteria, healing wounds, reducing cholesterol and cell lifespan

Here are the steps to follow: Contact a healthcare provider immediately : The first thing you should do is reach out to your doctor, healthcare provider, or a local poison control center